October 08, 2026 08:54 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar | India condemns Houthi attacks on Saudi airports, calls targeting of civilian infrastructure unacceptable | Dalal Street bloodbath: Investors lose Rs. 8 lakh crore as Sensex crashes over 1,000 points | Amazon layoffs hit India, US and UK: Fresh job cuts rock e-commerce giant amid festive shopping season | Bollywood mourns Nana Patekar: Anupam Kher, Akshay Kumar, Jr NTR, Suniel Shetty pay emotional tributes | ‘He was never wavering while expressing his opinions’: PM Modi mourns Nana Patekar | Nana Patekar dies at 75: Veteran actor suffers cardiac arrest at Goa home | RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50%
Covid-19 vaccines

Two Covid-19 vaccine candidates await DCGI approval for emergency use in India

| @indiablooms | Jan 03, 2021, at 04:24 pm

New Delhi/IBNS: Two Covid-19 vaccine candidates in India-Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield-now awaits the approval of the Drugs Controller General of India (DCGI) for emergency use after they have been cleared by the government-appointed panel.

DCGI chief Dr Venugopal G Somani is expected to share details about the vaccine candidates on Sunday.

The government-appointed panel of experts on Saturday cleared the emergency use of indigenous COVID-19 vaccine Covaxin manufactured by Hyderabad-based Bharat Biotech and recommended for approval to the regulator Drugs Controller General of India (DCGI).

The recommendation for the home-grown vaccine came a day after the expert panel cleared Covishield developed by Oxford University and pharma major AstraZeneca to be manufactured by Serum Institute of India (SII).

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) recommended the Drugs Controller General of India (DCGI) to grant permission to Bharat Biotech's Covaxin.

According to reports, the SEC met on Jan 1 and 2 and made the recommendations for the consideration and final decision of DGCI, said the Union Health Ministry.

The Serum Institute of India (SII) is making the vaccine Covishield developed by Oxford University and pharma major AstraZeneca, while Bharat Biotech has partnered with the Indian Council of Medical Research (ICMR) for its indigenous Covaxin.

The final decision to recommend Bharat Biotech's Covaxin came after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

The committee noted that the vaccine has the potential to target mutated coronavirus strains, media reports said.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.